CMN Weekly (21 February 2025) - Your Weekly CRISPR...
CMN Weekly
Feb. 21, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Prevail Therapeutics
Company type: Therapeutics
Main focus: Adeno-associated virus (AAV)-based therapies for neurodegenerative conditions
Company stage: Pre-clinical
Diseases: Parkinson’s disease, frontotemporal dementia, Alzheimer’s disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative disorders
Genome-editing tool:
Funding stage: Series B (now a fully owned subsidiary of Eli Lilly)
Location: New York, NY, USA
Website: https://www.prevailtherapeutics.com
Pipeline: https://www.prevailtherapeutics.com/programs/#our-pipeline
Partners: Regenxbio, Scribe Therapeutics
Prevail Therapeutics, a fully owned subsidiary of Eli Lilly, is leveraging adeno-associated virus serotype 9 (AAV9) to deliver gene therapeutics to address devastating neurogenerative disorders including Parkinson’s disease, frontotemporal dementia, Alzheimer’s disease, and Amyotrophic lateral sclerosis (ALS).
